Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

Sub-indication: Lung Cancer

Study Type: Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

Schedule an Appointment